CXCR3 and colorectal carcinoma: Interestingly, the percentage of CXCR3+CD8+ T cells was also lower in advanced-stage CRC compared with early stage, which was consistent with CD8+ T cell levels (Fig. 2b); a similar result was observed in CRC patients with distant metastasis compared with those without (Fig. 2c).